ten Velde G P, Kuypers-Engelen B T, Volovics A, Bosman F T
Department of Pulmonology, Academic Hospital Maastricht, The Netherlands.
Eur J Cancer. 1990;26(11-12):1142-5. doi: 10.1016/0277-5379(90)90272-u.
Bone marrow biopsy specimens were evaluated retrospectively in 63 of 88 (72%) patients with small cell lung cancer (SCLC). Significant differences were not found between extensive disease (ED) patients with or without bone marrow metastases in survival nor in nadirs of leucocytes or platelets subsequent to chemotherapy. A panel of antibodies was used to investigate whether immunohistochemical analysis on routinely processed bone marrow biopsy specimens could detect marrow metastases more effectively than conventional microscopy. In histologically proven marrow metastases and in control SCLC sections a combination of an antibody against cytokeratin 8, 18 and 19 (NCL5D3) and an antibody against neurone specific enolase was validated for detection of metastases. In histologically negative marrow biopsy samples, however, this combination did not yield any additional tumour positive cases. Therefore, histological evaluation of a bone marrow biopsy specimen, even when analysed by immunohistochemistry, does not contribute information relevant for staging, therapy evaluation or prognosis in SCLC.
对88例小细胞肺癌（SCLC）患者中的63例（72%）进行了骨髓活检标本的回顾性评估。广泛期疾病（ED）患者中，有或无骨髓转移者在生存率、化疗后白细胞或血小板最低点方面均未发现显著差异。使用一组抗体来研究对常规处理的骨髓活检标本进行免疫组化分析是否比传统显微镜检查能更有效地检测骨髓转移。在组织学证实的骨髓转移和对照SCLC切片中，一种针对细胞角蛋白8、18和19的抗体（NCL5D3）与一种针对神经元特异性烯醇化酶的抗体组合被验证可用于检测转移。然而，在组织学阴性的骨髓活检样本中，这种组合未产生任何额外的肿瘤阳性病例。因此，骨髓活检标本的组织学评估，即使通过免疫组化分析，也不会提供与SCLC分期、治疗评估或预后相关的信息。
